Granalix BioTechnologies

Company Overview

Snapshot

Founded in May 2013, Granalix BioTechnologies operates with 1–10 employees. The company focuses on developing science-based formulations of natural antioxidants for neurodegenerative conditions. In August 2020, studies highlighted that GranaGard, a pomegranate supplement, showed promise in slowing neurodegenerative diseases.

Business overview

Granalix BioTechnologies is a Health Tech & Life Sciences company focused on developing innovative, science-based formulations of natural antioxidants. Its core product, GranaGard, is a submicron self-emulsion of pomegranate seed oil, rich in punicic acid (PA), which converts into a neuroprotector in vivo. The company targets markets related to neurodegenerative conditions and aging, serving patients and consumers globally, with a presence in Israel, Mexico, Paraguay, and Greece.

Strategic signal

In August 2020, an Israeli supplement derived from pomegranate seed oil, GranaGard, demonstrated potential in improving cognitive function in multiple sclerosis patients and slowing neurodegenerative diseases. This development is significant as it validates the therapeutic potential of natural compounds in addressing complex neurological disorders, sending a positive signal to investors about Granalix BioTechnologies' product efficacy and market opportunity in the health and wellness sector.

Company Intelligence Q&A

What is Granalix BioTechnologies' flagship product?

Granalix BioTechnologies' flagship product is GranaGard, a submicron self-emulsion formulation of pomegranate seed oil, designed to deliver punicic acid (PA) as a natural antioxidant for neurodegenerative conditions.

What recent studies have shown about GranaGard?

In August 2020, studies indicated that GranaGard, a pomegranate supplement, showed promise in improving cognitive function in multiple sclerosis patients and slowing neurodegenerative diseases. This was further supported by a July 2020 announcement of a clinical trial by Rambam Medical Center to test GranaGard's impact on memory loss in patients with mild cognitive impairment.

When was GranaGard commercially launched?

Granalix BioTechnologies announced the commercial launch of GranaGard in September 2016, making it available for purchase on the company's website and in pharmacies in Mexico.

What is the scientific basis for GranaGard's efficacy?

GranaGard's efficacy is based on its formulation of pomegranate seed oil, which contains high concentrations of punicic acid (PA). In vivo, PA has been shown to convert into conjugated linoleic acid, an established neuroprotector and mitochondrial activity modulator, as highlighted in January 2018.

What markets does Granalix BioTechnologies serve?

Granalix BioTechnologies serves global markets, with products available in Israel, Mexico, Paraguay, and Greece, targeting individuals seeking natural solutions for neurodegenerative conditions and cognitive health.